Interstitial Cystitis Treatment Denied by Insurance? How to Appeal

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic condition that causes bladder pressure, pelvic pain, and urinary urgency and frequency. It disproportionately affects women — up to 90% of patients with IC are female. Despite the significant quality-of-life impact of this condition, IC/BPS patients routinely face insurance denials for diagnostic procedures and treatments.

What Is IC/BPS?

The American Urological Association (AUA) defines IC/BPS as an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with lower urinary tract symptoms of more than 6 weeks' duration, in the absence of infection or other identifiable causes.

IC/BPS is a diagnosis of exclusion — other causes of bladder symptoms must be ruled out first. The AUA Guideline for Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome (updated 2022) provides the clinical framework that should govern all coverage decisions for IC/BPS care.

Cystoscopy with Hydrodistension: Diagnostic and Sometimes Therapeutic

Cystoscopy with hydrodistension (filling the bladder to capacity under anesthesia) is used to:

1. Diagnose IC/BPS (identifying glomerulations or Hunner lesions)
2. Rule out other conditions (bladder cancer, structural abnormalities)
3. Provide temporary therapeutic relief for some patients

Insurers sometimes deny cystoscopy with hydrodistension for IC/BPS as "not medically necessary" or as a "screening procedure." However, the AUA IC/BPS guideline recognizes cystoscopy as an appropriate diagnostic and therapeutic tool in this patient population.

In your appeal:

• Specify that the procedure is diagnostic (ruling out other conditions and confirming IC/BPS diagnosis) — not elective screening
• Cite the AUA IC/BPS guideline as the clinical standard of care
• Include documentation of your symptoms, duration, prior negative urinalysis and cultures, and the clinical evaluation process

PTNS (Percutaneous Tibial Nerve Stimulation)

PTNS is a minimally invasive neuromodulation treatment for IC/BPS symptoms. It involves weekly 30-minute sessions where a small needle electrode is placed near the ankle to stimulate the tibial nerve, which modulates bladder function.

PTNS (Urgent PC system) is FDA-approved for overactive bladder and has been used for IC/BPS. Insurers frequently deny PTNS for IC/BPS by claiming:

• It is approved for OAB but not specifically IC/BPS
• It is "not medically necessary" for IC/BPS
• Conservative therapy was not failed first

Appeal strategy:

• Document that PTNS is an AUA guideline-endorsed neuromodulation option for IC/BPS
• Cite your prior failed conservative therapies (dietary modification, oral medications, pelvic floor PT, intravesical treatments)
• PTNS is less invasive and less costly than surgical alternatives — argue it represents appropriate conservative escalation before more invasive interventions

InterStim (Sacral Neuromodulation)

Sacral neuromodulation (SNM) via the Medtronic InterStim or Axonics Modulation device involves a surgically implanted device that delivers mild electrical pulses to the sacral nerves to modulate bladder function. It is FDA-approved for urgency urinary incontinence, urgency-frequency syndrome, and urinary retention.

Insurers require Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization for SNM implantation and frequently deny based on:

• Insufficient documentation of failed conservative therapies
• Questions about IC/BPS as an FDA-approved indication
• Cost concerns

The AUA IC/BPS guideline supports SNM as a fifth-line treatment after failure of less invasive therapies. Your appeal should document your complete treatment history — demonstrating that you have appropriately failed or are unable to tolerate first through fourth line treatments — and cite AUA guideline support for SNM as fifth-line therapy.

A trial (external) phase is typically performed before the permanent implant. If your trial phase was covered but the permanent implantation was then denied, appeal immediately citing the positive trial results and AUA guideline support for proceeding to implantation after a successful trial.

Intravesical Instillations (Bladder Instillations)

Intravesical instillations — where a solution is instilled directly into the bladder via catheter — are a core IC/BPS treatment. Common agents include:

• DMSO (dimethyl sulfoxide): The only FDA-approved intravesical treatment for IC
• Lidocaine and heparin: Commonly combined for immediate symptom relief ("rescue instillation")
• Sodium bicarbonate: Often added to lidocaine cocktails
• Hyaluronic acid (various formulations): Used internationally, limited US availability

Insurers frequently deny or limit intravesical instillations based on:

• Frequency limits (fewer instillations than prescribed)
• "Not medically necessary" for DMSO despite FDA approval
• Denial of compounded instillation cocktails

For DMSO denials, cite its FDA approval specifically for symptomatic IC. For lidocaine/heparin cocktail denials, cite AUA IC/BPS guideline support for intravesical therapies and your provider's clinical rationale.

How to Appeal IC/BPS Treatment Denials

Step 1: Build your treatment history timeline. Document all prior IC/BPS treatments — oral medications (Elmiron, tricyclics, antihistamines), dietary changes, pelvic floor PT, behavioral interventions — and their outcomes.

Step 2: Get a detailed letter from your urologist or urogynecologist. The letter should outline your diagnosis, treatment history, clinical rationale for the requested treatment, and cite AUA IC/BPS guidelines.

Step 3: Cite the AUA IC/BPS guideline specifically. Reference the specific treatment line in the AUA guideline that supports the requested service.

Step 4: File an internal appeal within 180 days. For ongoing treatments, request expedited review if your condition is deteriorating.

Step 5: Request peer-to-peer review. Having your urologist speak directly with the insurer's medical reviewer often resolves IC/BPS denials more effectively than written appeals alone.

Fight Back With ClaimBack

IC/BPS is a legitimate, debilitating condition with AUA guideline-endorsed treatments. ClaimBack helps you build the evidence-based appeal your insurer needs to see.

Start your free appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs. External Insurance Appeal: What's the Difference?